Patara Pharma Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Patara Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11331
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Patara Pharma Inc (Patara Pharma) is a clinical-stage biopharmaceutical company that develops novel therapies for the treatment of chronic inflammatory and fibrosis. The company develops anti-inflammatory therapeutics for lung diseases and immune disorders. It conducts clinical trials and initiates phase studies of anti-inflammatory therapeutics for the treatment of refractory chronic cough in patients diagnosed with idiopathic pulmonary fibrosis. The company’s pipeline products include PA101, a robust phase 2b clinical trial for patients with idiopathic pulmonary fibrosis, refractory chronic cough and indolent systemic mastocytosis. Patara Pharma is headquartered in San Diego, California, the US.

Patara Pharma Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Patara Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Patara Pharma Raises USD6 Million in Venture Financing 10
Patara Pharma Raises USD10.6 Million in Venture Financing 11
Patara Pharma Raises US$1.8 Million In Venture Financing Round 12
Licensing Agreements 13
Roivant Sciences Receives Rights from Patara Pharma 13
Equity Offering 14
Patara Pharma Raises USD26 Million in Private Placement of Preferred Stock 14
Patara Pharma Inc – Key Competitors 15
Patara Pharma Inc – Key Employees 16
Patara Pharma Inc – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Patara Pharma Inc, Pharmaceuticals & Healthcare, Key Facts 2
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Patara Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Patara Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Patara Pharma Raises USD6 Million in Venture Financing 10
Patara Pharma Raises USD10.6 Million in Venture Financing 11
Patara Pharma Raises US$1.8 Million In Venture Financing Round 12
Roivant Sciences Receives Rights from Patara Pharma 13
Patara Pharma Raises USD26 Million in Private Placement of Preferred Stock 14
Patara Pharma Inc, Key Competitors 15
Patara Pharma Inc, Key Employees 16

List of Figures
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Patara Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Patara Pharma Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Riot Blockchain Inc (RIOT):企業の財務・戦略的SWOT分析
    Riot Blockchain Inc (RIOT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Oncternal Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Oncternal Therapeutics Inc (Oncternal) is a clinical-stage oncology company that develops therapies for rare and common cancers. The company’s pipeline compounds include cirmtuzumab and TK216. Its compounds are primarily focused on exciting targets which are uniquely expressed within cancer …
  • ContourGlobal LP-エネルギー分野:企業M&A・提携分析
    Summary ContourGlobal L.P. (CGLP) is an energy company that owns and operates of power generation assets. It develops, acquires and operates electric power and district heating businesses. The company develops and operates large central power plants in emerging markets to support the growth of the n …
  • Selventa Inc-製薬・医療分野:企業M&A・提携分析
    Summary Selventa Inc (Selventa), formerly Genstruct Inc is a healthcare technology services provider that operates life science consulting projects. The company offers system diagnostic development services that identifies molecular mechanisms, networks and biomarkers to develop therapeutics, molecu …
  • Epinex Diagnostics Inc:企業の製品パイプライン分析2018
    Summary Epinex Diagnostics Inc (Epinex Diagnostics) is a medical device company that develops rapid diagnostic tests. The company’s products include over-the-counter test device, Epinex G1A Test system, Epinex ACR Test system, Epinex SimplySure PT-INR Test system and point-of-care test device, among …
  • Open Text Corporation:企業のM&A・事業提携・投資動向
    Open Text Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Open Text Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Alpiq Holding AG:企業の戦略的SWOT分析
    Alpiq Holding AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • First Security Bank Inc:企業の戦略・SWOT・財務情報
    First Security Bank Inc - Strategy, SWOT and Corporate Finance Report Summary First Security Bank Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Henry Schein, Inc.:企業の戦略・SWOT・財務情報
    Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report Summary Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Piramal Enterprises Ltd (PEL):医療機器:M&Aディール及び事業提携情報
    Summary Piramal Enterprises Ltd (PEL), is a provider of medicines and healthcare finance services. The company offers products such as Critical Care, Consumer Care, BST-CarGel, Phyto Medicines, Anaesthesias, Orthopedic medicines, Halothane, Isoflurane , Sevoflurane and other OTC related medicines. I …
  • Renaissance Oil Corp (ROE):石油・ガス:M&Aディール及び事業提携情報
    Summary Renaissance Oil Corp (Renaissance Oil), formerly San Antonio Ventures Inc is an oil and gas exploration and development company that acquires and develops high potential shale and mature fields in Mexico. The company utilizes seismic technology and advanced structural interpretation for the …
  • Syndax Pharmaceuticals Inc (SNDX):企業の財務・戦略的SWOT分析
    Summary Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the tre …
  • ChemImage Corp:企業の製品パイプライン分析
    Summary ChemImage Corp (ChemImage) is a molecular chemical imaging company that provides hyperspectral imaging technologies. The company develops molecular chemical imaging devices and data fusion tools for anatomic structure imaging, cancer detection and cardiovascular health assessment. It offers …
  • Elixir Energy Ltd (EXR):企業の財務・戦略的SWOT分析
    Summary Elixir Energy Ltd (Elixir Energy) is an independent oil and gas exploration and production company that acquires, explores, and develops conventional and unconventional oil and gas properties. The company's projects include Petra project, Wattenberg project, and Moselle Permit. Its Petra pro …
  • Endava Limited
    Endava Limited - Strategy, SWOT and Corporate Finance Report Summary Endava Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Khatam al-Anbia:企業の戦略的SWOT分析
    Khatam al-Anbia - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Opthea Ltd (OPT)-製薬・医療分野:企業M&A・提携分析
    Summary Opthea Ltd (Opthea), formerly Circadian Technologies Ltd is a provider of research and development of angiogenesis and vascular leakage-based treatments for cancer focusing on vascular endothelial growth factors. The company’s pipeline products comprise VEGF-C, VEGF-D and VEGFR-3. Opthea’s d …
  • Technicolor SA:企業の戦略・SWOT・財務情報
    Technicolor SA - Strategy, SWOT and Corporate Finance Report Summary Technicolor SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Telus Corp (T):企業の財務・戦略的SWOT分析
    Telus Corp (T) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Navitas Ltd:企業の戦略的SWOT分析
    Navitas Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆